par Verlooy, J;Mosseri, V;Bracard, S;Tubiana, A Lellouch;Kalifa, C;Pichon, F;Frappaz, D;Chastagner, P;Pagnier, A;Bertozzi, A-I;Gentet, J C;Sariban, Eric 
;Rialland, X;Edan, C;Bours, D;Zerah, M;Le Gales, C;Alapetite, C;Doz, F
Référence European journal of cancer, 42, 17, page (3004-3014)
Publication Publié, 2006-11
;Rialland, X;Edan, C;Bours, D;Zerah, M;Le Gales, C;Alapetite, C;Doz, FRéférence European journal of cancer, 42, 17, page (3004-3014)
Publication Publié, 2006-11
Article révisé par les pairs
| Résumé : | AIM: Improvement of EFS of children older than 3 years with high risk medulloblastoma. METHODS: Between 1993 and 1999, 115 patients (3-18 years, mean 8 years) with high risk medulloblastoma were included. After surgery treatment consisted of chemotherapy ('8in1' and etoposide/carboplatin) before and after craniospinal radiotherapy. RESULTS: Patients were staged using Chang-criteria (PF residue only, M1 and M2/M3) by local investigator as well as by central review panel (82.4% concordance). Chemotherapy was well tolerated without major delays in radiotherapy. With a mean follow up of 81 months (9-119), 5-year EFS was 49.8% and OS 60.1%. In detail according to subgroups EFS was 68.8% for PF residue only, 58.8% for M1 disease and 43.1% for M2/M3. CONCLUSION: M1 patients are legitimate high risk patients. Survival rates are still very low for high risk medulloblastoma patients and future trials should therefore focus on more intensive (chemotherapy/radiotherapy) treatment. |
